Skip to main content
. Author manuscript; available in PMC: 2010 Mar 1.
Published in final edited form as: Nat Neurosci. 2009 Aug 16;12(9):1129–1135. doi: 10.1038/nn.2372

Figure 4. Pharmacological suppression of parkin/PINK1 mutant phenotypes by rapamycin.

Figure 4

(a) Thoracic indentations, (b) climbing ability, and (c) number of dopaminergic neurons in parkin and PINK1 mutants fed rapamycin or vehicle (DMSO). (d-f) TEM of muscle sections from control (DMSO) treated wild type, parkin and PINK1 mutants. (g-i) TEM of muscle sections from rapamycin fed wild type, parkin and PINK1 mutants Scale bars show 2μm. Wild types are out-crossed heterozygous mutations. Charts show mean and SEM. Significance determined by Student’s t-test (*** P<0.001, ** P<0.01).